New data from the RELY-ABLE study have provided additional support to the safety profile and efficacy of Pradaxa(R) (dabigatran etexilate) for stroke prevention in patients with nonvalvular atrial fibrillation (AF) over a period in excess of 2 years.[*][1]

The new long-term results presented at the American Heart Association's (AHA) Scientific Sessions, are consistent with the findings from the RE-LY trial[*]. The rates of stroke and haemorrhage observed during an additional 2.3 years of blinded follow-up in RELY-ABLE correspond to the initial RE-LY results, with the benefit of both doses of dabigatran etexilate sustained throughout the study's duration.[1]-[3] 

Twelve-month data from the Global Anticoagulant Registry in the FIELD (GARFIELD) show that the poor management of stroke prevention therapy is widespread in clinical practice, which may lead to elevated rates of mortality, stroke and bleeding among individuals with newly diagnosed atrial fibrillation (AF).

Researchers have observed the quantum regime in the interaction between nano-sized spheres of gold, thanks to the change of color of the gap between these particles when they are at distances of less than one nanometer.

They have literally 'seen' a quantum kiss between nanoparticles.

The fossilized fangs of saber-toothed cats, a leopard-sized Promegantereon ogygia and a much larger, lion-sized Machairodus aphanistus, hold clues to how large, extinct mammals once shared space and food with other large predators 9 million years ago.

Paleontologists have analyzed the tooth enamel of two species of saber-toothed cats and a bear dog unearthed in geological pits near Madrid. Bear dogs, also extinct, had dog-like teeth and a bear-like body and gait. 

Autologous stem cells from bone marrow 3 or 7 days following a heart attack did not improve heart function six months later, according to a new clinical trial. 

The results of this TIME (Transplantation In Myocardial Infarction Evaluation) trial were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation Tuesday, today at the 2012 Scientific Sessions of the American Heart Association in Los Angeles.

The results of this trial mirror a previous, related study (LateTIME) which found that autologous bone marrow stem cell therapy given 2-3 weeks after a heart attack did not improve cardiac recovery. Both TIME and LateTIME were carried out by the Cardiovascular Cell Therapy Research Network (CCTRN).

People with heart health in middle age may live up to 14 years longer, free of cardiovascular disease, compared to peers who have two or more cardiovascular disease risk factors, according to a new paper.

For the analysis, researchers pulled data from five different cohorts included in the Cardiovascular Lifetime Risk Pooling Project and looked at the participants' risk of all forms of fatal and nonfatal cardiovascular disease from ages 45, 55 and 65 through 95 years of age.